Previous immunohistochemistry studies reported VEGFR2 expression in high-grade prostate intra-epithelial neoplasia and carcinomas of the prostate [40–42], whereas gene expression findings evidenced expression of KDR mRNA in prostate cancer cell lines and a functional impact of using a KDR antisense oligonucleotide in suppressing cell proliferation and promoting apoptosis [43, 44]. The gene discussed is KDR; the disease is prostate carcinoma.